Recce Pharmaceuticals Ltd (ASX:RCE) has received encouraging results for its antiviral SARS-CoV-2 screening program RECCE 327 (R327) from the Peter Doherty Institute for Infection and Immunology that shows that it has the ability to prevent the growth of the SARS-CoV-2 virus.
According to the company, R327 has shown encouraging inhibition and is advancing to Stage 1b, which is to begin in a few weeks at the Doherty Institute in Melbourne.
“Highly encourage by the results”
Recce non-executive chairman John Prendergast said: “We’re highly encouraged by the results from this study, which indicate anti-viral activity of R327 and, in particular, highlight the potential potency of our lead candidate against SARS-CoV-2.
“We are interested in seeing the next stage and look forward to continuing research on the effectiveness of R327 with the team at the Doherty Institute.”
Ongoing study in the US
In parallel to the CSIRO and Doherty Institute studies in Australia, a contract research organisation in the US is advancing in their in-vivo studies of RECCE compounds against SARS-CoV-2 in ferrets.
These studies continue to progress well with results on-track for year-end 2020.
According to the company, the engagement of the US organisation has not resulted in any material benefits at this stage, however, if there are any material results from the studies, it will announce later.
Recce’s chief executive officer James Graham outlined the company progress during today’s Proactive Biotech Webinar.
This presentation, along with others by Pharmaxis Ltd (ASX:PXS) and Cynata Therapeutics Ltd (ASX:CYP) can be viewed by clicking this link.
